New mRNA flu shot enters early human testing
NCT ID NCT05945485
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new mRNA flu vaccine in 50 healthy adults aged 18 to 49. The vaccine uses mRNA technology to target a specific flu strain. Researchers will compare its safety and immune response to a standard seasonal flu shot. The goal is to see if the new vaccine is safe and triggers a strong immune reaction.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mRNA vaccine (DCVC H1 HA mRNA-LNP)
- What this could lead to
- If successful, this could lead to a new type of flu vaccine that is quicker to update and produce.
- What could go wrong
- This is a very early Phase 1 trial with only 50 people. The vaccine may not work as hoped, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Iowa - Infectious Disease Clinic
Iowa City, Iowa, 52242, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Flu vaccine showdown: which shot protects seniors best?
- Can a simple breath test catch flu in High-HIV regions?
- Can a simple mask stop the flu? 2,000 volunteers put it to the test
- Can a stronger flu shot better protect seniors?
- Flu shot showdown: Cell-Grown vs recombinant vaccine put to the test
- New mRNA vaccine aims to outsmart flu by targeting its hidden parts